Meet the 2017 Rock Docs

See past Rock Docs »

David DeNardo, PhD
Associate Professor of Medicine and Pathology and Immunology

Dr. DeNardo is a tumor Immunologist specializing in pancreatic cancer. His focus is to develop and optimize immunotherapeutic strategies for pancreatic and other cancers. His lab aims to improve the understanding of how immune responses shape and are shaped by malignancies. Dr. DeNardo received his PhD at Baylor and has been a member of the Washington University faculty since 2011 and is presently a member of Siteman Cancer Center.



Andrea Hagemann, MD, MSCI
Associate Professor of Obstetrics & Gynecology

Dr. Hagemann graduated from Washington University School of Medicine and completed her OB/GYN residency at Barnes-Jewish Hospital. During her gynecologic oncology fellowship at the University of Pennsylvania, she performed research on immunotherapy for ovarian cancer. Dr. Hagemann returned to Washington University as a faculty member in 2011 and is presently a member of the Siteman Cancer Center.  Her clinical focus is on surgery and chemotherapy for ovarian, uterine, cervical and vulvar/vaginal cancers. Her research interests focus on healthy survivorship and prevention of cancer through weight management and appropriate genetic testing. In addition to being a Rock Doc, Dr. Hagemann is a team captain with Pedal the Cause, Siteman Cancer Center’s annual benefit to create a world without cancer. She is passionate about partnering with her patients to understand, confront, prevent and cure gynecologic cancer.

Albert H. Kim, MD, PhD               
Associate Professor of Neurological Surgery, Neurology and Developmental Biology, Surgical Director of the Pituitary Center,  Co-Leader of Neuro-Oncology Research Focus Group at Siteman Cancer Center, Co-Leader of the Neurorestorative Therapy Group at Hope Center

Dr. Kim is a brain tumor surgeon and scientist who received his MD/PHD at NYU and completed his residency at Harvard-affiliated Brigham & Women’s Hospital and Boston Children's Hospital. In addition to performing open surgery and minimally invasive procedures to remove both malignant and benign brain tumors, Dr. Kim’s laboratory focuses on understanding the molecular mechanisms that drive brain tumor cell growth and therapy resistance using a unique resource of human brain tumor specimens, through a methodology developed by Dr. Kim and his team.  Dr. Kim told us that “major advances in clinical treatment, clinical trials, and the basic biology of central nervous system tumors are occurring at Siteman Cancer Center and nationally in neuro-oncology, and I have great optimism about our growing ability to control and potentially cure brain tumors.” He is presently a member of Siteman Cancer Center.


Lindsay Peterson, MD, MSCR    
Assistant Professor of Medicine, Division of Medical Oncology

Dr. Peterson is a medical oncologist who completed her MD at Tulane University and is now dedicated to taking care of women and men with breast cancer. Dr. Peterson sees patients at Siteman’s South County location and her research interests center on determining how lifestyle (including nutrition, weight management and exercise) following a diagnosis of breast cancer can affect outcomes such as risk of recurrence as well as outcomes important to quality of life such as fatigue and other treatment-related side effects.


Josh Rubin, MD, PhD
Professor of Pediatrics and Neuroscience, Co-Director of Pediatric Neuro-Oncology at St. Louis Children’s Hospital, Co-Leader of Solid Tumor Therapeutics Program at Siteman Cancer Center

More males get malignant brain tumors than females and the reason for this are not understood- Dr. Rubin is studying the molecular basis and clinical implications of sex differences in brain tumors. His lab has identified significant differences in cellular growth regulation and the efficacy of standard chemotherapy agents when tested against male and female cells. These results may form the basis of future clinical trials for brain cancer. Dr. Rubin completed his MD and PhD at the Albert Einstein College of Medicine and completed his postgraduate training at Harvard-affiliated Boston Children’s Hospital and the Dana Farber Cancer Institute. He is presently a member of Siteman Cancer Center.


Julie Schwarz, MD, PhD
Associate Professor and Cancer Biology Division Director Department of Radiation Oncology

Dr. Schwarz received her MD/PhD and completed her residency at Washington University. In clinical practice, Dr. Schwarz treats women with radiation for gynecologic cancer. In the laboratory, her team uses molecular biology, genetic engineering and small animal imaging to answer fundamental questions about tumor biology and the biology that drives tumor appearance on diagnostic images Her current focus is understanding the connection between tumor glucose metabolism and radiation therapy resistance. She is presently a member of Siteman Cancer Center.